Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024
Provided By GlobeNewswire
Last update: Nov 14, 2024
Cullinan will present new in vitro preclinical data that provide further strong rationale for broad clinical development of CLN-978 in autoimmune diseases
Cullinan will share details of global Phase 1b study in moderate to severe systemic lupus erythematosus
Read more at globenewswire.comNASDAQ:CGEM (12/19/2025, 2:36:18 PM)
9.81
-0.17 (-1.7%)
Find more stocks in the Stock Screener
